The company's medical test platform monitors the proportion of circulating tumor DNA in a patient's blood sample to determine how they are responding to therapy, enabling clinicians to monitor treatment response in near real-time. This allows for rapid decision-making on the choice of therapy, reducing unnecessary side effects and improving patient quality of life and survival rates. CCG aims to use increasing amounts of clinical and genomic data to develop data-driven biomarkers indicative of treatment response, ultimately predicting the best therapeutic strategy for cancer patients before they even begin treatment.